Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) has said it will sponsor TheraPsil, a British Columbia (BC)-based non-profit coalition of healthcare professionals, policy-makers and community leaders seeking legal access to psilocybin for BC palliative cancer patients in psychological distress.
The firm, which focuses on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for nutraceutical and psychedelic medicines, said the TheraPsil coalition will start in 2020 with a focus on compassionate access to psychedelic-assisted therapy for those in medical need, public education to increase awareness of the treatments, professional training to develop protocols for to deliver psilocybin-assisted therapy, and research collaborations with Canadian and international partners.
READ: Champignon Brands inks deal for California's Wellness Clinic of Orange County as part of North American expansion strategy
In a statement, Pat McCutcheon, director at Champignon, said: “Through our sponsorship, the Champignon team and board are extremely proud to begin collaborating alongside TheraPsil, helping patients in palliative care access new and effective therapies. Together we will work to provide countless Canadians facing a palliative cancer diagnosis, along with their families, who also face severe psychological distress, with the treatment options, compassion and hope they deserve.”
“We’re really happy to have this support to get the ball rolling on this project to help palliative Canadians. We are dedicated to giving those at end-of-life the treatment options they deserve - and that includes psilocybin. We believe that as a non-profit, and with the right support, we can get these patients their right to treatment with psilocybin in a timely manner”, added Bruce Tobin, founder of TheraPsil.
Contact the author at calum@proactiveinvestors.com
Follow him on Twitter @Cal_Proac